Developer docs
API playgroundTry for free, no card

Search company profiles

Mondego Bio

Full company profile

uuid000434b

Namestring
Mondego Bio
Legal namestring
Mondego Bio
Websiteurl
mondegobio.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Mondego Bio is a clinical-stage biotechnology company headquartered at Biocant Park in Cantanhede, Portugal, developing next-generation small-molecule immuno-oncology therapies. The company's lead program targets PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2), a negative regulator of the JAK-STAT pathway whose inhibition enhances IFNγ sensing and signaling to overcome immune resistance in solid tumors. Lead clinical candidate ZE00-0388 is an orally bioavailable, highly selective PTPN2 inhibitor that has demonstrated strong PTPN2/PTPN1 inhibitory activity, selectivity against other phosphatases, favorable preclinical safety, and complete and sustained tumor regression in MC38 colon cancer models when combined with anti-PD-1 therapy.

The company was incubated through Expert Systems' AI/ML-driven discovery platform in collaboration with Eilean Therapeutics (the origination science platform co-founded by OrbiMed and Torrey Pines) and Molsoft LLC. Mondego Bio integrates rational design, computational pharmacology, and medicinal chemistry to advance ZE00-0388 into a dual-track Phase 1 first-in-human study planned for H1 2026, covering both healthy volunteers and oncology patients. Manufacturing and clinical readiness are supported by an extended partnership with ChemDiv, giving the program cross-border infrastructure across Europe and the U.S.

Mondego Bio is pre-revenue and private, with no commercialized products. Its intended revenue model is pharmaceutical commercialization of PTPN2 inhibitors for oncology — both as monotherapy and in combination with immune checkpoint inhibitors — supplemented by potential licensing and royalty arrangements. The company completed Series A financing in September 2025 led by Biovance Capital with participation from OrbiMed and Torrey Pines Investment, which is funding the transition from discovery to clinical-stage operations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCantanhede, Portugal
HQ citystring
Cantanhede
HQ countrystring
Portugal
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule immuno-oncology, PTPN2 inhibitor therapy, cancer immunotherapy drugs, AI-driven drug discovery, clinical-stage biotech
Industry2 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Immuno-Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotechnology company. Revenue model will be based on commercialization of PTPN2 inhibitor therapies for oncology. The company was incubated through Expert Systems AI/ML-driven discovery platform and is advancing ZE00-0388 into Phase 1 clinical trials in H1 2026.

mondegobio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mondego Bio is a clinical-stage biotechnology company developing best-in-class PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) small-molecule inhibitors for cancer immunotherapy. Its lead clinical candidate ZE00-0388 is an AI-designed, highly selective PTPN2 inhibitor that enhances IFNγ sensing and signaling through the JAK-STAT pathway, intended as monotherapy or in combination with immune checkpoint inhibitors to overcome resistance in solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Complete and sustained tumor regression achieved in preclinical MC38 colon cancer models when ZE00-0388 combined with anti-mPD-1 therapy, persisting even after discontinuation of checkpoint inhibitor treatment
Product overview1 text field

Mondego Bio is a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies. The company is developing best-in-class PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) inhibitors using AI/ML-driven molecular design. The primary product is ZE00-0388, a highly selective small-molecule PTPN2 inhibitor that enhances IFNγ sensing and signaling to improve cancer immunotherapy efficacy. The company integrates rational design, computational pharmacology, and medicinal chemistry expertise, incubated through the AI-driven discovery platform of Expert Systems in collaboration with Eilean Therapeutics and Molsoft LLC.

Product and service1 record
1ZE00-0388 (PTPN2 Inhibitor Clinical Candidate)
CategoryImmuno-Oncology Therapeutics / Small-Molecule Drug Candidate
Description

AI-designed, highly selective small-molecule inhibitor of PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) intended as a next-generation immuno-oncology therapy for solid tumors. Demonstrates strong PTPN2/PTPN1 inhibitory activity, outstanding selectivity against all other phosphatases, high oral bioavailability, and favorable safety profiles; induces tumor cell susceptibility to IFNγ and suppresses tumor growth. Intended for use as monotherapy and in combination with immune checkpoint inhibitors (e.g., anti-PD-1) for oncology patients.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

ChemDiv announced an extension of its partnership with Mondego Bio to develop PTPN2 immuno-oncology programs. The collaboration involves drug discovery, scale-up manufacturing, and accelerating clinical readiness, supported by ChemDiv's and Mondego's facilities across Europe and the U.S.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

Expert Systems Inc., a leading drug discovery accelerator, announced the Series A funding and launch of Mondego Bio. Expert Systems provided AI/ML-driven molecular design platform that facilitated the discovery and development of Mondego Bio's PTPN2 inhibitors for immuno-oncology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-18
Description

Lead programs are based on research initially developed by Eilean Therapeutics, an AI/ML supported oncology platform co-founded by OrbiMed and Torrey Pines. Mondego Bio integrates rational design, computational pharmacology, and medicinal chemistry expertise to target intracellular regulators relevant to immune modulation and cancer biology.

Strategic tierSupportingTypeTechnology or Integration
Description

Mondego Bio was incubated through the AI- and machine-learning-driven discovery platform of Expert Systems, in collaboration with Eilean Therapeutics and Molsoft LLC.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mondego Bio

Immuno-Oncology Therapeuticsmondegobio.com

What Mondego Bio does

Mondego Bio is a clinical-stage biotechnology company headquartered at Biocant Park in Cantanhede, Portugal, developing next-generation small-molecule immuno-oncology therapies. The company's lead program targets PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2), a negative regulator of the JAK-STAT pathway whose inhibition enhances IFNγ sensing and signaling to overcome immune resistance in solid tumors. Lead clinical candidate ZE00-0388 is an orally bioavailable, highly selective PTPN2 inhibitor that has demonstrated strong PTPN2/PTPN1 inhibitory activity, selectivity against other phosphatases, favorable preclinical safety, and complete and sustained tumor regression in MC38 colon cancer models when combined with anti-PD-1 therapy.

The company was incubated through Expert Systems' AI/ML-driven discovery platform in collaboration with Eilean Therapeutics (the origination science platform co-founded by OrbiMed and Torrey Pines) and Molsoft LLC. Mondego Bio integrates rational design, computational pharmacology, and medicinal chemistry to advance ZE00-0388 into a dual-track Phase 1 first-in-human study planned for H1 2026, covering both healthy volunteers and oncology patients. Manufacturing and clinical readiness are supported by an extended partnership with ChemDiv, giving the program cross-border infrastructure across Europe and the U.S.

Mondego Bio is pre-revenue and private, with no commercialized products. Its intended revenue model is pharmaceutical commercialization of PTPN2 inhibitors for oncology — both as monotherapy and in combination with immune checkpoint inhibitors — supplemented by potential licensing and royalty arrangements. The company completed Series A financing in September 2025 led by Biovance Capital with participation from OrbiMed and Torrey Pines Investment, which is funding the transition from discovery to clinical-stage operations.

Mondego Bio firmographics

Firmographics
Name
Mondego Bio
Legal name
Mondego Bio
Website
https://mondegobio.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Mondego Bio industry classification

Industry
Product category
Immuno-Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Small molecule immuno-oncology
  • PTPN2 inhibitor therapy
  • Cancer immunotherapy drugs
  • AI-driven drug discovery
  • Clinical-stage biotech

Where Mondego Bio is headquartered

Location

Headquarters

HQ city
Cantanhede
HQ country
Portugal
HQ region
Europe

Offices1 record

Markets served

Mondego Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company. Revenue model will be based on commercialization of PTPN2 inhibitor therapies for oncology. The company was incubated through Expert Systems AI/ML-driven discovery platform and is advancing ZE00-0388 into Phase 1 clinical trials in H1 2026.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Mondego Bio product offering

Product offering

Core offering

Mondego Bio is a clinical-stage biotechnology company developing best-in-class PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) small-molecule inhibitors for cancer immunotherapy. Its lead clinical candidate ZE00-0388 is an AI-designed, highly selective PTPN2 inhibitor that enhances IFNγ sensing and signaling through the JAK-STAT pathway, intended as monotherapy or in combination with immune checkpoint inhibitors to overcome resistance in solid tumors.

Product overview

Mondego Bio is a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies. The company is developing best-in-class PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) inhibitors using AI/ML-driven molecular design. The primary product is ZE00-0388, a highly selective small-molecule PTPN2 inhibitor that enhances IFNγ sensing and signaling to improve cancer immunotherapy efficacy. The company integrates rational design, computational pharmacology, and medicinal chemistry expertise, incubated through the AI-driven discovery platform of Expert Systems in collaboration with Eilean Therapeutics and Molsoft LLC.

Differentiator

Problem solved

Functional benefit

Products and services

  • ZE00-0388 (PTPN2 Inhibitor Clinical Candidate) AI-designed, highly selective small-molecule inhibitor of PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) intended as a next-generation immuno-oncology therapy for solid tumors. Demonstrates strong PTPN2/PTPN1 inhibitory activity, outstanding selectivity against all other phosphatases, high oral bioavailability, and favorable safety profiles; induces tumor cell susceptibility to IFNγ and suppresses tumor growth. Intended for use as monotherapy and in combination with immune checkpoint inhibitors (e.g., anti-PD-1) for oncology patients.

Quantifiable outcome

  • Complete and sustained tumor regression achieved in preclinical MC38 colon cancer models when ZE00-0388 combined with anti-mPD-1 therapy, persisting even after discontinuation of checkpoint inhibitor treatment

Companies that use Mondego Bio

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Mondego Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Mondego Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • ChemDivcoreStrategic or Co-development Partner · 24 October 2025ChemDiv announced an extension of its partnership with Mondego Bio to develop PTPN2 immuno-oncology programs. The collaboration involves drug discovery, scale-up manufacturing, and accelerating clinical readiness, supported by ChemDiv's and Mondego's facilities across Europe and the U.S.
  • Expert Systems Inc.coreStrategic or Co-development Partner · 29 September 2025Expert Systems Inc., a leading drug discovery accelerator, announced the Series A funding and launch of Mondego Bio. Expert Systems provided AI/ML-driven molecular design platform that facilitated the discovery and development of Mondego Bio's PTPN2 inhibitors for immuno-oncology.
  • Eilean TherapeuticscoreStrategic or Co-development Partner · 18 September 2025Lead programs are based on research initially developed by Eilean Therapeutics, an AI/ML supported oncology platform co-founded by OrbiMed and Torrey Pines. Mondego Bio integrates rational design, computational pharmacology, and medicinal chemistry expertise to target intracellular regulators relevant to immune modulation and cancer biology.
  • Molsoft LLCsupportingTechnology or IntegrationMondego Bio was incubated through the AI- and machine-learning-driven discovery platform of Expert Systems, in collaboration with Eilean Therapeutics and Molsoft LLC.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Mondego Bio competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Mondego Bio social profiles

Digital presence

Mondego Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mondego Bio leadership team

Management profile

Number of profiles

Profiles9 records

Mondego Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mondego Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mondego Bio

What does Mondego Bio do?

Mondego Bio is a clinical-stage biotechnology company developing best-in-class PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) small-molecule inhibitors for cancer immunotherapy. Its lead clinical candidate ZE00-0388 is an AI-designed, highly selective PTPN2 inhibitor that enhances IFNγ sensing and signaling through the JAK-STAT pathway, intended as monotherapy or in combination with immune checkpoint inhibitors to overcome resistance in solid tumors.

Is Mondego Bio a public or private company?

Mondego Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mondego Bio founded?

Mondego Bio was founded in 2025. It employs 1 to 10 people.

Where is Mondego Bio based?

Mondego Bio is headquartered in Cantanhede, Portugal, in the Europe region.

How does Mondego Bio make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Does Mondego Bio have an API?

No public API is recorded for Mondego Bio.

What industry is Mondego Bio in?

Mondego Bio's product category is Immuno-Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMondego Bio Initiates First-in-Human Study of MB‑388, an Oral Dual PTPN2/PTPN1 Inhibitor Designed to Overcome Resistance to Cancer ImmunotherapyMondego Bio initiated a first-in-human Phase 1a study of MB-388, an oral dual PTPN2/PTPN1 inhibitor, in healthy volunteers to assess safety, pharmacokinetics, and target engagement. The company plans a Phase 1b study in patients with advanced solid tumors in January 2027, with initial human PK and PD data expected in December 2026.PR NewswireMondego Bio Initiates First-in-Human Study of MB‑388, an Oral Dual PTPN2/PTPN1 Inhibitor Designed to Overcome Resistance to Cancer ImmunotherapyMondego Bio initiated a first-in-human Phase 1a study of MB-388, an oral dual PTPN2/PTPN1 inhibitor, in healthy volunteers to assess safety, pharmacokinetics, and target engagement. The company plans a Phase 1b study in patients with advanced solid tumors in January 2027, with initial human PK and PD data expected in December 2026.PR NewswireMondego Bio Announces Selection of a PTPN2 Inhibitor Clinical Candidate and Targets First-in-Human Trials in H1 2026Mondego Bio announced the selection of ZE00-0388, a selective PTPN2 inhibitor, as its lead clinical candidate for immuno-oncology therapy. The company plans to initiate first-in-human Phase 1 trials in the first half of 2026 following successful preclinical evaluations. This milestone is supported by Series A financing led by Biovance Capital with participation from OrbiMed and Torrey Pines Investment.PR NewswireChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology ProgramChemDiv extended its discovery and early development partnership with Mondego Bio to advance its PTPN2 immuno-oncology program. The collaboration leveraged rational drug design across reversible, covalent, and allosteric inhibitors, advancing Mondego's pre-IND program. ChemDiv will continue providing medicinal chemistry, CMC, and pharmacology support.PR NewswireExpert Systems Inc., a leading drug discovery accelerator, proudly announces the Series A funding and launch of Mondego Bio, an emerging immuno-oncology company headquartered at Biocant Park in CantanExpert Systems Inc. announced the launch of Mondego Bio, an immuno-oncology company, following Series A funding. Mondego Bio is developing PTPN2 inhibitors to enhance cancer immunotherapy, using AI/ML-driven drug design supported by Expert Systems.YahooExpert Systems Inc., a leading drug discovery accelerator, proudly announces the Series A funding and launch of Mondego Bio, an emerging immuno-oncology company headquartered at Biocant Park in CantanExpert Systems Inc. announced Series A funding and the launch of Mondego Bio, an immuno-oncology company, backed by Biovance Capital, Torrey Pines Investment, and OrbiMed. Mondego Bio is advancing a portfolio of PTPN2 inhibitors for cancer immunotherapy, with Expert Systems providing ongoing support as the company moves toward first-in-human studies.FinSMEsMondego Bio Raises Series A FundingMondego Bio, a Lisbon-based PTPN2 inhibitor developer, raised an undisclosed Series A led by Biovance Capital Partners, Orbimed, and Torrey Pines Investment. The funds will expand operations and development efforts for its immuno-oncological therapy with improved safety and tolerability.MondegobioBiovance Capital leads Series A Financing in Mondego Bio together with OrbiMed and Torrey PinesBiovance Capital, with OrbiMed and Torrey Pines, led Series A financing for Portuguese cancer startup Mondego Bio. The company develops PTPN2 inhibitors as a potential immuno-oncological therapy. The round marks Biovance Capital Fund I's inaugural investment.PR NewswireBiovance Capital leads Series A Financing in Mondego Bio together with OrbiMed and Torrey PinesBiovance Capital, OrbiMed, and Torrey Pines led a Series A financing for Portuguese startup Mondego Bio, which develops PTPN2 inhibitors for immuno-oncology. The round marks Biovance Capital Fund I's first investment, with the lead programs based on research from Eilean Therapeutics.